Compliance with recommendations of clinical practice in the management of venous thromboembolism in cancer: The CARMEN study

Sevestre, Marie‐Antoinette; Bélizna, C.; Durant, C.; Bosson, Jean‐Luc; Védrine, Lionel; Cajfinger, Francis; Debourdeau, Philippe; Farge, Dominique

doi:10.1016/j.jmv.2014.03.001

Cited by 51 publications

(30 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This is particularly true for the use of LMWHs in the treatment of cancer-associated VTE. Many patients still continue to receive VKAs, and if LMWHs are given, they are often underdosed or terminated prematurely [21,22,23,24,25,26,27,28,29,30,31]. With the advent of the DOACs, the preference of the guidelines for LMWHs over any of these newer agents will be challenged.…”

Section: Introductionmentioning

confidence: 99%

Treatment of Venous Thromboembolism in Ambulatory Cancer Patients in Germany: A Prospective Non-Interventional Study

Matzdorff

Schilling²,

Ledig³

2015

Oncol Res Treat

View full text Add to dashboard Cite

Background: Venous thromboembolism (VTE) is a serious threat for all cancer patients. This study was aimed to assess the VTE treatment of cancer patients in the ambulatory care setting. Patients and Methods: This is a prospective non-interventional study, which includes ambulatory cancer patients from office-based oncologists. A standardized case report form was used to obtain data on patient characteristics, treatment regimens, duration of treatment, and side effects. Results: Specialists from 34 centers included data from 76 patients. The median patient age was 62 years (range 33-81 years). The 4 most common cancer types were breast cancer (32%), colorectal cancer (18%), lymphoma and lung cancer (each 8%). 18% of the acute VTE cases were treated as inpatients, 80% as outpatients, and 99% with low-molecular-weight heparin (LMWH), unfractionated heparin (UFH), or fondaparinux. After the acute phase, secondary prophylaxis with LMWH/UFH/fondaparinux was planned in 61% of the patients, with oral anticoagulation in 39%. During acute-phase treatment and secondary prophylaxis, no patient had recurrent VTE. 4 patients (5%) experienced minor bleedings. Conclusions: This study shows that many ambulatory cancer patients with VTE have early tumors, no metastases, and an excellent performance score. Most patients receive LMWHs for secondary prophylaxis, as recommended by the national and international guidelines. Still, a relevant percentage is switched to oral anticoagulants.

show abstract

Section: Introductionmentioning

confidence: 99%

Treatment of Venous Thromboembolism in Ambulatory Cancer Patients in Germany: A Prospective Non-Interventional Study

Matzdorff

Schilling²,

Ledig³

2015

Oncol Res Treat

View full text Add to dashboard Cite

show abstract

“…The incidence of thrombosis is higher in the first few months after the diagnosis of cancer. VTE is particularly common in the most aggressive and advanced cancers [21,22,23,24]. [25,26,27,28].…”

Section: Discussionmentioning

confidence: 99%

Thrombosis and Cancer: Case Series of 25 Patients

Kaddouri¹

2017

AJIM

View full text Add to dashboard Cite

Abstract:The objective of this paper is to describe the clinical and therapeutic characteristics of thrombosis associated with cancers in patients in charge of the internal medicine-oncology department of the Ibn Sina Military Hospital in Marrakech. This is a retrospective, descriptive and analytical study over a two-year period from January 2013 to December 2014. Among 158 patients with cancer, we identified 25 with thrombosis confirmed by imaging. Characteristics of the population of origin, incidence, risk factors for venous thromboembolic disease (VTE), diagnostic means, distribution of thrombosis, location and histological type of cancer and therapeutic strategy were analyzed. The mean age of our patients was 55.89 years, with female predominance (56% vs 44%). The incidence of venous thrombosis in our series is 15.8% (n = 25) of which 76% (n = 19) are isolated, 12% (n = 3) are on central venous catheter (CVC) and 12% (n = 3) are associated with pulmonary embolism. The lower limbs were the most affected (80.3%), with predominance on the left side. Bilateral involvement was found in 7% of cases. Thrombosis was indicative of cancer in 16% of patients (n = 4). While it complicated the development in 84% of the cases (n = 21). Risk factors for VTE were dominated by females (56%), metastases (64%), chemotherapy (80%), and the presence of a CVC (80%). Solid tumors were the most frequent 72% (n = 18) with predominantly digestive cancers (28%), pulmonary (16%), bladder (16%) and breast (12%). The most predominant histological type was adenocarcinoma in 44% (n = 11). The seven cases of malignant hemopathies are: four non-Hodgkin's lymphomas, two multiple myelomas and one case of chronic myeloid leukemia. The initial curative treatment as a relay used low molecular weight heparin in 92% of patients (n = 23). Unfractionated heparin was used in two patients with severe renal failure, the only ones receiving vitamin K antagonist maintenance therapy. Short-term outcomes were favorable in 92% (n = 23), two deaths Have been attributed to severe pulmonary embolism. Significant progress has been made in the context of cancer-related VTE. Nevertheless, there remains a considerable field of unresolved clinical issues. Numerous studies are underway and may lead to advances not only in the treatment of VTE associated with cancer but also in the treatment of the cancerous disease itself.

show abstract

“…[58,59] Recommendations for thromboprophylaxis in colorectal surgery patients are based on the once-daily administration and shows a lower risk of heparin-induced thrombocytopenia. [30] The CARMEN study [60] is an interesting French observational study, in with the researchers evaluated the adhesion to guidelines for treatment of VTE in hospitalized patients. Among cancer patients, 64% had metastatic disease.…”

Section: Vte Prophylaxis and Treatment In Cancer Patients: Evidences mentioning

confidence: 99%

“…Cancer sites were gastro-intestinal (25%), gynecologic (23), pulmonary (21%), hematological (14%), urologic (10%) or other (8%). [60] It was observed that after laparoscopic surgery for colorectal cancer, extended antithrombotic prophylaxis (4 weeks) is safe and reduces the risk for VTE as compared with 1-week prophylaxis.…”

Section: Vte Prophylaxis and Treatment In Cancer Patients: Evidences mentioning

confidence: 99%

Venous Thromboembolism and Colorectal Cancer: A Review

Ding¹

2017

WJPR

View full text Add to dashboard Cite

Venous thromboembolism is a common complication of malignancies and epidemiological studies suggested that colorectal cancer belong to the group of malignancies with the highest incidence rates of VTE.Risk factor for VTE in colorectal cancer patients are advanced disease, colorectal surgery and chemotherapy including anti-angiogenic therapy.Other risk factors are pretreatment platelet counts and increased release of TF-positive micro-particles. Elevated D-dimer level do not necessarily indicate an increased risk of VTE but have been shown to be predictive for a worse clinical outcome in colorectal cancer patients.Mechanisms responsible for the increase in venous thrombosis in patients with colorectal cancer are not understood. Currently no biomarker is recognized as a predictor for VTE in colorectal cancer.Although several clinical trials have reported the efficacy of antithrombotic prophylaxis in patients with colorectal cancer who are receiving chemotherapy, further trials are needed to assess the clinical benefit since these patients are at an increased risk of developing a thromboembolism.

show abstract

Compliance with recommendations of clinical practice in the management of venous thromboembolism in cancer: The CARMEN study

Cited by 51 publications

References 21 publications

Treatment of Venous Thromboembolism in Ambulatory Cancer Patients in Germany: A Prospective Non-Interventional Study

Treatment of Venous Thromboembolism in Ambulatory Cancer Patients in Germany: A Prospective Non-Interventional Study

Thrombosis and Cancer: Case Series of 25 Patients

Venous Thromboembolism and Colorectal Cancer: A Review

Contact Info

Product

Resources

About